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Abstract
Background: Clinical spectrum, microbiology and outcome of empyema thoracis are changing.
Intrapleural instillation of fibrinolytic agents is being increasingly used for management of empyema
thoracis. The present study was carried out to describe the clinical profile and outcome of patients
with empyema thoracis including those with chronic empyema and to study the efficacy and safety
of intrapleural streptokinase in its management.
Methods: Clinical profile, etiological agents, hospital course and outcome of 31 patients (mean age
40 ± 16 years, M: F 25: 6) with empyema thoracis treated from 1998 to 2003 was analyzed. All
patients were diagnosed on the basis of aspiration of frank pus from pleural cavity. Clinical profile,
response to therapy and outcome were compared between the patients who received intrapleural
streptokinase (n = 12) and those who did not (n = 19).
Results: Etiology was tubercular in 42% of the patients (n = 13) whereas the rest were bacterial.
Amongst the patients in which organisms could be isolated (n = 13, 42%) Staphylococcus aureus was
the commonest (n = 5). Intrapleural streptokinase was instilled in 12 patients. This procedure
resulted in increase of drainage of pleural fluid in all patients. Mean daily pleural fluid drainage after
streptokinase instillation was significantly higher for patients who received intrapleural
streptokinase than those who did not (213 ml vs 57 ml, p = 0.006). Only one patient who was
instilled streptokinase eventually required decortication, which had to be done in five patients
(16.1%). Mean hospital stay was 30.2 ± 17.6 days whereas two patients died.
Conclusions:  Tubercular empyema is common in Indian patients. Intrapleural streptokinase
appears to be a useful strategy to preserve lung function and reduce need for surgery in patients
with late stage of empyema thoracis.
Background
Empyema thoracis refers to the collection of pus in the
pleural cavity. There has been significant change in micro-
biology and course of empyema thoracis [1,2]. Despite
availability and widespread usage of highly effective anti-
biotics, empyema thoracis occurs and is associated with
significant morbidity and occasional mortality. Early
drainage of pus from the pleural cavity along with broad-
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spectrum antibiotics is the cornerstone of treatment.
Intercostal tube drainage (ICTD) is the usual mode of pus
drainage. But ICTD is hampered by the presence of either
thick pus, which tends to block the tube or the presence of
multiple loculations that cannot be drained by a single
chest tube. To overcome such problems surgical proce-
dures like rib resection and open drainage were done in
the past. These surgical procedures have been supple-
mented by safer and less invasive surgical procedures like
video assisted thoracoscopic surgery (VATS) [3]. Although
these surgical procedures have been a major step forward
in search of lesser invasive approach for management of
empyema thoracis, they still carry the risk of significant
morbidity, lack free availability and costs involved remain
prohibitive [4]. Use of fibrinolytic agents for intrapleural
instillation has provided an option of managing these
patients without subjecting them to surgical procedures.
This therapeutic modality helps to break the loculations
by virtue of its fibrinolytic property [5]. Although this
approach has gained popularity in recent years, first use of
fibrinolytic therapy was reported in 1949 [6]. But signifi-
cant systemic side effects were seen at that time with use
of unpurified fibrinolytic agents. This led to a loss of inter-
est in the technique and it was only three decades later
that a purified form of streptokinase was shown to
improve outcome without causing any significant sys-
temic side effects [7]. Since then, many studies have dem-
onstrated the same to be a safe and effective strategy [8,9].
Most of these studies evaluating the role of intrapleural
streptokinase (IPSTK) have been comprised of patients
with empyema at an early stage. The spectrum of patients
with empyema thoracis in the Indian subcontinent is dif-
ferent from the West due to high prevalence of tubercular
empyema. Because of this, a large number of patients tend
to present with chronic empyema [10]. Data from India
on utility of IPSTK in empyema thoracis is only limited to
a few case reports [11,12]. Utility of IPSTK in a cohort
comprising of significant number of patients with tuber-
cular empyema has not been reported. Similar concerns
were raised in a recent review as well [13].
This study was carried out with the goal of studying the
safety and efficacy of this technique in Indian patients
with empyema thoracis. We also describe the etiological
agents, clinical features, hospital course and outcome of
these patients.
Methods
Thirty one patients with empyema thoracis admitted to
single medical unit of Department of Medicine of All
India Institute of Medical Sciences (AIIMS), New Delhi,
India (a tertiary care center) admitted over a 6-year period
(1998 to 2003) were included in a retrospective fashion.
All patients were admitted with a diagnosis of empyema
thoracis secondary to different causes. Diagnosis of
empyema thoracis was based on demonstration of frank
pus upon pleural fluid aspiration prior to admission.
None of the included patients was at the stage of non-
empyematous complicated para-pneumonic effusion.
Clinical profile in the form of history, associated co-mor-
bid conditions, and physical examination, laboratory
parameters including complete hemogram, serum chem-
istry, urine examination and hematological, biochemical
and microbiological characteristics of pleural fluid were
recorded. Serology (ELISA) for human immuno-defi-
ciency virus (HIV) was done for all patients as described
before [14].
Pleural fluid was examined for Gram stain, smear for acid-
fast bacilli (AFB) and cultured for pyogenic organisms and
Mycobacterium tuberculosis (Lowenstein Jensen media) in
all patients [15]. In addition to chest radiograph, compu-
terized tomography (CT) of the chest was done for all
patients. All patients were managed with insertion of
ICTD. Except in cases where a large free collection was
present, ICTD was inserted under ultrasound (US) guid-
ance. Follow up US and/or CT chest were done and repo-
sitioning, removal or insertion of a second chest tube was
carried out as per the need to achieve maximum drainage.
Broad-spectrum antibiotics were also used. All patients
received a combination of at least two or more antibiotics
including metronidazole, third generation cepha-
losporins and cloxacillin. Four-drug anti-tuberculosis
treatment (ATT) (rifampicin, isoniazid, pyrazinamide and
ethambutol) was initiated in cases with tubercular etiol-
ogy [16]. Daily drainage of pleural fluid from the pleural
cavity was recorded for each patient.
As IPSTK was not used freely for management of patients
with empyema thoracis in AIIMS during the initial years
of the study, patients enrolled during that phase did not
receive IPSTK (n = 19). Among the patients from the later
years, IPSTK was routinely instilled (n = 12). Injection
streptokinase (250,000 IU) (Thrombosolv, VHB life sci-
ences, India) was dissolved in 100 ml normal saline and
instilled in the pleural cavity through the ICTD by clamp-
ing the distal end. After instillation, the tube was clamped
for four hours and the patient asked to repeatedly change
position and move around so that streptokinase (STK)
could thoroughly spread in the pleural cavity. At the end
of 4 hrs, the clamp was opened and amount of drainage,
in addition to the saline instilled, was recorded. One cycle
of IPSTK instillation comprised of three doses, each of
250,000 IU given every 12 hours, so that three doses of
IPSTK were instilled by the next morning (at 0, 12, and 24
hours). Depending on the response and need, another
cycle of three doses of 250,000 IU was initiated the next
morning, thereby providing an interval of at least 24
hours between the two cycles. Such a schedule resulted inBMC Infectious Diseases 2004, 4:19 http://www.biomedcentral.com/1471-2334/4/19
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an average dose of 375,000 IU/day. All patients were
closely watched for development of any side effects such
as fever, chills, allergic reactions and bleeding. Evidence of
hypersensitivity to STK (not seen in any patient) and pres-
ence of associated broncho-pleural fistula (n = 4) were
contraindications for IPSTK instillation.
All other therapeutic strategies, both medical and surgical
including decortication were recorded for all patients. In
addition, days of hospital stay as well as survival to dis-
charge was recorded.
Statistical analysis
Data were collected using a pre-designed data entry sheet.
Data were double entered to minimize error and managed
on a 'Microsoft Excel' spreadsheet. Analysis was done
using statistical software 'SPSS version 10.0' (SPSS Inc,
Chicago, IL, USA). Study group was divided in to IPSTK
group (received IPSTK, n = 12) and non-IPSTK group (did
not receive IPSTK, n = 19) and various parameters were
compared between the two groups. For continuous varia-
bles, normality of distribution was assessed. Normally
distributed variables were summarized as mean with
standard deviation and compared between the two groups
using Student's t-test. Other continuous variables were
described as median with range and compared using
Mann-Whitney U test. Fisher exact test was applied to
compare the ordinal variables. Statistical significance was
considered at P < 0.05 (only two tailed) for the present
study.
Results
Clinical profile
Mean age of the patients was 40 ± 16 years (range 15–80
years). Males dominated the study group (n = 25, 80.6%).
Mean duration of symptoms was 144 days (range 3 days
to 3 years). Diabetes mellitus was the commonest co-mor-
bidity (5 patients, 16.1%). Thirteen patients had evidence
of underlying pulmonary tuberculosis (42%). Rest of the
patients had para-pneumonic effusion. Chest pain was
the commonest symptom (90.3%) followed by cough
(87.1%) and fever (83.9%). Right side was more fre-
quently involved (n = 17, 54.8%) as compared to left side
(n = 12, 38.7%). Two patients had bilateral empyema tho-
racis. Signs of volume loss on ipsilateral side (61.3%) and
clubbing (29%) were common. Four patients had clinical
evidence of associated broncho-pleural fistula. The clini-
cal profile of IPSTK and non-IPSTK groups have been
compared in Table 1.
Laboratory profile
Various laboratory parameters have been compared
between the two groups (IPSTK and non-IPSTK group) in
Table 1. None of the parameters were significantly differ-
ent between the two groups. Biochemical examination of
pleural fluid revealed exudative nature of the fluid with
low glucose in all patients. A majority of patients (n = 26,
83.9%) had neutrophil dominance in the pleural fluid
whereas the rest had effusion with lymphocytic predomi-
nance (n = 5, 16.1%). All patients were HIV sero-negative.
Microbiological characteristics
Organisms could be isolated from 13 patients out of
which  Staphylococcus aureus was the commonest (6
patients, 46.2%). Rest of the patients grew gram-negative
organisms, namely Pseudomonas aeruginosa (n = 5), Kleb-
siella pneumoniae (n = 4) and Escherichia coli (n = 2). More
than one organism was isolated in four patients. Smear as
well as culture for Mycobacterium tuberculosis was negative
for all patients. None of the patients grew any organism in
blood or sputum cultures.
Imaging
CT chest was done for all patients. Loculations with pleu-
ral enhancement were seen in all patients. Prominent loss
of lung volume on the side of empyema thoracis was seen
in 20 patients (64.5%). Parenchymal lesions suggestive of
pulmonary tuberculosis were seen in 13 patients (42%).
These lesions consisted of typical fibro-parenchymal
lesions with evidence of cavitation in apical regions of the
lung suggestive of active disease. In addition, presence of
mediastinal lymphadenopathy with central necrosis was
seen in eight patients. Response to IPSTK was studied in
all patients who received STK by a repeat CT chest. Radio-
logical improvement in the form of reduction is the size
of collection and partial to complete expansion of the
underlying lung was seen in all patients.
Treatment
All patients received a combination of antibiotics. Metro-
nidazole was used in 70% of the patients followed by
cephalosporins and aminoglycoside in 58% patients and
cloxacillin in 48% patients. Thirteen patients (42%) were
given ATT. All were treated on the basis of pulmonary
parenchymal lesions strongly suggestive of active tubercu-
losis and/or mediastinal lymphadenopathy with central
necrosis on CT chest. ICTD was done for all patients.
IPSTK was instilled in 12 patients. This procedure resulted
in increase of pleural fluid drainage in all the patients.
Mean daily pleural fluid drainage after STK instillation
was significantly higher for IPSTK group (213 ml vs 57 ml,
p = 0.006, figure 1). Mean cumulative drainage of pleural
fluid was also significantly higher for patients who
received IPSTK (1665 ml vs 800 ml, p < 0.001). No signif-
icant difference in pleural fluid drainage was seen
between patients with tubercular empyema and those
with non-tubercular empyema. Only one patient in IPSTK
group eventually required decortication, as compared to
four in the other group (8.3% vs 21%, p = NS). Mean hos-
pital stay was 30.2 ± 17.6 days whereas 2 patients died.BMC Infectious Diseases 2004, 4:19 http://www.biomedcentral.com/1471-2334/4/19
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Cause of death was refractory hypotension with extensive
PTB in one patient and sepsis with multi-organ failure in
other. These parameters were not different for the two
groups.
Discussion
This retrospective study indicates the microbiology and
changing trends in the management of empyema thoracis
and emerging role of fibrinolytic therapy in management
of empyema thoracis at a late stage. Organisms could be
isolated from pleural fluid in 42% of patients. Rates of
microbiological diagnosis in earlier studies have been in
the range of 31–72% [7,17], which are similar to what we
found. Staphylococcus aureus was the commonest amongst
the microbiological isolates. Rest of the isolates were
gram-negative organisms. Many earlier reports from the
West have indicated the rising incidence of Staphylococcus
aureus as a cause of empyema thoracis [18] and the same
seems to be true for patients from India as well. Gram-
negative organisms are also frequently isolated, presuma-
bly, because of high incidence of resistance of these organ-
isms to commonly used antibiotics in the early phase of
pneumonia. None of the patients grew streptococci or any
anaerobic organism. This also is in accordance with earlier
reports where streptococci were rarely if ever seen as a
cause of empyema [18,19]. More than one isolate was
found in four patients (31%). Polymicrobial etiology of
empyema thoracis is also well documented [19]. This jus-
tifies the use of combination of antibiotics as an empirical
form of treatment. On the basis of isolates in the present
series, a combination of at least an anti-staphylococcal
antibiotic with another antibiotic having activity against
gram-negative organisms seems to be appropriate. A large
percentage of patients (58%) received aminoglycosides.
This is somewhat unexpected, as penetration of aminogly-
cosides in the pleural space is known to be poor [20].
Many of these patients would have received aminoglyco-
sides for other indications such as underlying pneumonia.
In addition, this pattern of use probably reflects the prob-
lems related to the treatment costs. Most of the patients
admitted to our center are from low socio-economic strata
and are not able to afford costly drugs such as cepha-
losporins and the same are not available freely in the hos-
pital supply. In most of these cases, aminoglycosides
would be given for providing gram-negative coverage.
Tubercular etiology was found in 13 patients (42%). This
is higher as compared to an earlier series from India.
Gupta and coworkers [2] reported an incidence of 29% in
1989. But it was also observed that this was significantly
Table 1: Characteristics of patients who received intrapleural streptokinase (IPSTK group, n = 12) and those who did not (Non IPSTK 
group, n = 19)
Parameters IPSTK group (n = 12) Non IPSTK group (n = 19) P value
Age (years) 40 ± 15 41 ± 17 0.87
Sex (male/female) 9/3 16/3 0.53
Duration of symptoms (months)* 2.0 (0.2–12) 1.5 (0.1–36) 0.49
Chronic Empyema† 9 (75%) 11 (57.9%) 0.32
Hemoglobin (gm/dL) 10.1 ± 2.6 9.6 ± 2.0 0.63
TLC (/cmm) 11,100 ± 5489 14,494 ± 8271 0.19
ESR (1st hr) 46 ± 19 57 ± 24 0.17
Blood Urea (mg/dL) 36 ± 15 41 ± 21 0.08
Serum creatinine (mg/dL) 1.2 ± 0.5 1.3 ± 0.8 0.64
Serum sodium (meq/L) 135.7 ± 4.1 134.9 ± 7.3 0.69
Serum potassium (meq/L) 4.3 ± 0.8 4.1 ± 0.4 0.38
Total bilirubin (mg/dL) 0.6 ± 0.3 0.8 ± 0.5 0.06
AST (IU/L)* 28 (17–218) 32 (12–381) 0.48
ALT (IU/L)* 19 (10–295) 33 (10–461) 0.54
SAP (IU/L) 203 ± 110 200 ± 105 0.95
Serum albumin (gm%) 2.9 ± 0.7 3.1 ± 0.7 0.54
Pl F total cells (/cmm)* 5000 (500–90,000) 2500 (800–160,000) 0.25
Pl F neutrophil count (/cmm)* 4500 (500–85,000) 2000 (100–150,000) 0.21
Pl F protein (gm/dL) 4.9 ± 1.1 4.4 ± 1.8 0.29
Pl F glucose (mg/dL)* 32 (0–80) 12 (3–70) 0.17
Presence of loss of lung volume 8 (66.7%) 12 (63.2%) 0.84
Tubercular empyema 6 (50%) 7 (36.8%) 0.47
TLC: Total leukocyte count, ESR: Erythrocyte sedimentation rate, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, SAP: Serum 
alkaline phosphatase, Pl F: Pleural fluid. Data is presented as mean ± standard deviation except those variables marked by a * where data is 
presented as median with range. †Patients with duration of symptoms more than 4 weeks were designated as having chronic empyemaBMC Infectious Diseases 2004, 4:19 http://www.biomedcentral.com/1471-2334/4/19
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lower than what had been reported in various earlier
reports from 1970–1985 [1,10,22] where tuberculosis
was responsible for majority of the patients with
empyema thoracis. Mycobacterium tuberculosis could not
be isolated from any of the patients with tubercular
empyema. All these patients were diagnosed on the basis
of radiological features like pulmonary fibro-parenchy-
mal lesions (n = 13) or necrotising lymphadenopathy (n
= 8). In contrast to figures from the West where isolation
rates of Mycobacterium tuberculosis from pus have been very
high, Indian studies have consistently reported low isola-
tion rates. Jha and coworkers (1972) [1] found AFB in
empyema fluid in only 1 out of 24 patients (4.2%)
whereas in a relatively recent series, AFB could not be iso-
lated from any of the 29 patients with tubercular
empyema [10]. The cause of this phenomenon is not clear
and needs further evaluation.
The main aim of this report was to study the utility of
IPSTK in patients with empyema thoracis from a region
where chronic empyema is common. This is an important
exercise as IPSTK has been shown, predominantly, to be
(A) CT chest of patient with loculated empyema thoracis (arrow) and (B) marked resolution following intrapleural streptoki- nase therapy Figure 2
(A) CT chest of patient with loculated empyema thoracis (arrow) and (B) marked resolution following intrapleural streptoki-
nase therapy. (C) Empyema thoracis and (D) significant improvement after intrapleural streptokinase therapy in another 
patient.
A
C
B
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effective in acute empyema. Twelve patients in whom loc-
ulations had been demonstrated on CT chest received
IPSTK. It was demonstrated that IPSTK was consistently
associated with marked increase in the pleural fluid drain-
age. All patients who received STK had been on ICTD
alone, to start with, before loculations could be demon-
strated on CT chest (mean duration on ICTD alone prior
to instillation of IPSTK: 5.2 days; range: 4–7 days).
Because of this, increase in drainage following instillation
of STK could be quantitated and radiologically docu-
mented. (Figure 1 &2). On the other hand, drainage of
those patients who did not receive STK showed a gradual
decline (Figure 1). In addition, requirement of a surgical
procedure was reduced in patients who received STK. Sim-
ilar finding was also reported by Davies et al [8] although
Chin and Lim [9] did not find any such advantage.
Many authors have reported the efficacy and safety of
intra-pleural fibnrinolytic agents (Table 2) [8,9,23-31]. In
addition to substantiating the same findings, the present
study serves to document the efficacy of IPSTK in a partic-
ular subset of patients. Till now, the use of STK has been
mostly restricted to patients with empyema in the early
phase of the disease. This is the stage of complicated para-
pneumonic effusion when loculations have just formed
and fibrin peel is being laid on pleural surface. At this
stage maximum breakdown of loculations and dissolu-
tion of fibrin peel is expected to occur. There is no doubt
that this is the stage when fibrinolytic therapy appears to
have the most desirable effect. Almost complete preserva-
tion of lung function can be expected. Nonetheless, the
results of the present study indicate that IPSTK may also
be useful in a late stage of empyema thoracis. That present
study did include such patients is obvious from many fac-
tors including a long duration of illness prior to
Mean pleural fluid drainage 5 days before and 5 days after intrapleural streptokinase (IPSTK) instillation for the two groups, ↓  :time of starting streptokinase instillation Figure 1
Mean pleural fluid drainage 5 days before and 5 days after intrapleural streptokinase (IPSTK) instillation for the two groups, ↓ 
:time of starting streptokinase instillationBMC Infectious Diseases 2004, 4:19 http://www.biomedcentral.com/1471-2334/4/19
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admission in majority of the patients and a large number
of patients with signs of volume loss on CT chest. Presence
of a large number of patients with tubercular empyema (n
= 13, 42%) in each group (IPSTK group 6/12 & non-IPSTK
group 7/19) also supports the same fact. It appears that
even in patients at a late stage of empyema, IPSTK resulted
in significant breakdown of loculations (Figure 2A and
2B). The reason for this could be the higher dose of IPSTK
used in this study. Also, even at a late stage of an active dis-
ease, new loculations are being formed which are likely to
be lysed by STK. The use of IPSTK at the dose used in the
present study (average dose 375,000 IU /day for 3–5 days)
was not associated with any obvious systemic effects,
although coagulation profile was not done for any
patient. Therefore, we would like to suggest that in a
patient who presents at a late stage of empyema thoracis,
a trial of fibrinolytic therapy must be considered. In such
patients a higher dose of IPSTK (375,000 IU/day) may be
given if drainage does not improve with 250,000 IU/day.
These patients should undergo repeat imaging to evaluate
the need for further instillation of STK as well as reposi-
tioning of chest tube if required. Such an approach is
likely to yield the best results with maximum preservation
of lung function and avoidance of any major surgical pro-
cedure. The relatively small sample size and retrospective
design are drawbacks of the present study and the results
need to be substantiated by a larger prospective trial in the
future.
Conclusions
Empyema thoracis is associated with significant morbid-
ity. Tubercular empyema is common in Indian setting but
rates of isolation of Mycobacterium tuberculosis from pus
are low. Corroborative evidence in the form of suggestive
radiology is utilized for supporting the diagnosis. Even in
patients with late stage of empyema thoracis, IPSTK
appears to be a useful strategy to preserve lung function
and reduce need for surgery.
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